The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness

Transfusion

Volumn 56, Issue 7, 2016, Pages 1849-1856

  Verduin, Esther P ^a,b   Brand, Anneke ^b   van de Watering, Leo M G ^a,b   Roelen, Dave L ^b   Kanhai, Humphrey H H ^b   Doxiadis, Ilias I N ^b   Claas, Frans H J ^b   Schonewille, Henk ^a,b  

^a Center for Clinical Transfusion Reseach Sanquin LUMC   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIBODY; HLA ANTIBODY; HLA DRB1 15 ANTIGEN; HLA DRB1 ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; GENE FREQUENCY; HLA TYPING; HOMOZYGOSITY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SEX RATIO;

EID: 84977668368     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13648     Document Type: Article

References (56)

1. Zhu Y, Zou L, Liu YC. T follicular helper cells, T follicular regulatory cells and autoimmunity. Int Immunol 2016;28:173-9.
2. Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007;47:2066–71.
3. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014;54:1981–7.
4. Körmöczi GF, Mayr WR. Responder individuality in red blood cell alloimmunization. Transfus Med Hemother 2014;41:446–51.
5. Yazdanbakhsh K. Mechanisms of sickle cell alloimmunization. Transfus Clin Biol 2015;22:178–81.
6. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015;168:291–300.
7. Tatari-Calderone Z, Tamouza R, Le Bouder GP, et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol 2013;2013:937846.
8. Hoppe C, Klitz W, Vichinsky E, et al. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol 2009;84:462–4.
9. Castilho SL, Vianna TV, Frauches TF, et al. Correlation between HLA class II (HLA-DRB1*) with the red cell alloimmunization in patients with sickle cell disease. Vox Sang 2015;109 SupplS1:254.
10. Sippert EA, Araújo Botelho MA, Rodrigues CR, et al. Positive association of HLA-DRB1*15 with RH alloimmunization in polytransfused patients with sickle cell disease (SCD). Vox Sang 2015;109 SupplS1:293.
11. Reviron D, Dettori I, Ferrera V, et al. HLA-DRB1 alleles and Jk(a) immunization. Transfusion 2005;45:956–9.
12. Picard C, Frassati C, Basire A, et al. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Transfusion 2009;49:2412–7.
13. Noizat-Pirenne F, Tournamille C, Bierling P, et al. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 2006;46:1328–33.
14. Chiaroni J, Dettori I, Ferrera V, et al. HLA-DRB1 polymorphism is associated with Kell immunisation. Br J Haematol 2006;132:374–8.
15. Chu CC, Ho HT, Lee HL, et al. Anti-“Mi(a)” immunization is associated with HLA-DRB1*0901. Transfusion 2009;49:472–8.
16. Schonewille H, Doxiadis II, Levering WH, et al. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion 2014;54:1971–80.
17. Moritz E, Souza CP, Cruz B, et al. HLA-DRB1*12 and HLA-DRB1*15 are associated with antibody response to RHD-antigen in Brazilians. Vox Sang 2015;109 SupplS1:376.
18. Pinheiro de Souza CS, Moritz EM, Chiba AK, et al. Association between HLA-DRB1 alleles and RBC alloimmunization in Brazilians. Vox Sang 2015;109 SupplS1:376–7.
19. Suciu-Foca N, Liu Z, Harris PE, et al. Indirect recognition of native HLA alloantigens and B-cell help. Transplant Proc 1995;27:455–6.
20. Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996;348:850–3.
21. Dankers MK, Roelen DL, Nagelkerke NJ, et al. The HLA-DR phenotype of the responder is predictive of humoral response against HLA class I antigens. Hum Immunol 2004;65:13–9.
22. Papassavas AC, Barnardo MC, Bunce M, et al. Is there MHC Class II restriction of the response to MHC Class I in transplant patients? Transplantation 2002;73:642–51.
23. Schonewille H, van de Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630–5.
24. Schonewille H, Klumper FJ, van de Watering LM, et al. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol 2007;196:143.e1–6.
25. Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996;6:111–4.
26. Buetens O, Shirey RS, Goble-Lee M, et al. Prevalence of HLA antibodies in transfused patients with and without red cell antibodies. Transfusion 2006;46:754–6.
27. McPherson ME, Anderson AR, Castillejo M, et al. HLA immunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010;54:552–8.
28. Schönbacher M, Heinzl MW, Dauber EM, et al. Granulocyte-reactive antibodies are associated with red blood cell alloimmunization. Vox Sang 2014;107:200–3.
29. Nickel RS, Hendrickson JE, Yee MM, et al. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Br J Haematol 2015;170:247–56.
30. Lechler RI, Heaton T, Barber L, et al. Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses. Immunol Lett 1992;34:63–9.
31. Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993;177:1643–50.
32. Verduin EP, Lindenburg IT, Smits-Wintjens VE, et al. Long-Term follow up after intra-Uterine transfusionS; the LOTUS study. BMC Pregnancy Childbirth 2010;10:77
33. Schreuder GM, Hendriks GF, D'Amaro J, et al. An eight-year study of HLA typing proficiency in Eurotransplant. Tissue Antigens 1986;27:131–41.
34. Verduyn W, Doxiadis II, Anholts J, et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 1993;37:59–67.
35. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570–4.
36. Prat E, Tomaru U, Sabater L, et al. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol 2005;167:108–19.
37. Voorter CE, Drent M, van den Berg-Loonen EM. Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA-DQB1*0602-DRB1*150101. Hum Immunol 2005;66:826–35.
38. Zhang Q, Lin CY, Dong Q, et al. Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev 2011;10:474–81.
39. Nowak J, Wozniak J, Mendek-Czajkowska E, et al. Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria. Cell Biochem Biophys 2013;65:321–33.
40. Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2008;105:13069–74.
41. Simon K, Schmidt H, Loud S, et al. Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis. Mult Scler 2015;21:703–9.
42. Bux J, Mueller-Eckhardt G, Mueller-Eckhardt C. Autoimmunization against the neutrophil-specific NA1 antigen is associated with HLA-DR2. Hum Immunol 1991;30:18–21.
43. Karpatkin S, Fotino M, Gibofsky A, et al. Association of HLA-DRw2 with autoimmune thrombocytopenic purpura. J Clin Invest 1979;63:1085–8.
44. Zota V, Nemirovsky A, Baron R, et al. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 2009;183:3522–30.
45. Bendtzen K, Morling N, Fomsgaard A, et al. Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988;28:599–606.
46. Lincoln MR, Ramagopalan SV, Chao MJ, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2009;106:7542–7.
47. Kreisler JM, Rementeria MC, de Pablo R, et al. HLA-DR2, a marker for class I antigen sensitization. Transplantation 1988;45:1071–4.
48. Heise E, Manning C, Thacker L. HLA phenotypes of ESRD patients are risk factors in the panel-reactive antibody (PRA) response. Clin Transplant 2001;15Suppl6:22–7.
49. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009;7:2006–15.
50. Irizar H, Muñoz-Culla M, Zuriarrain O, et al. HLA-DRB1*15:01 and multiple sclerosis: a female association? Mult Scler 2012;18:569–77.
51. Sayad A, Akbari MT, Pajouhi M, et al. Investigation the role of gender on the HLA-DRB1 and -DQB1 association with type 1 diabetes mellitus in Iranian patients. Cell J 2013;15:108–15.
52. Chao MJ, Ramagopalan SV, Herrera BM, et al. MHC transmission: insights into gender bias in MS susceptibility. Neurology 2011;76:242–6.
53. Lagaaij EL, Hennemann IP, Ruigrok M, et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321:701–5.
54. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127–31.
55. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008;6:225–34.
56. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505–12.